Continuous infusion of ceftazidime in the empiric treatment of febrile neutropenic children with cancer

Journal of Pediatric Hematology/Oncology

Volumn 24, Issue 9, 2002, Pages 714-716

  Dalle, Jean Hugues ^a,c   Gnansounou, Magloire ^b   Husson, Marie Odile ^a   Lambilliotte, Anne ^a   Mazingue, Françoise ^a   Nelken, Brigitte ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Hôpital de Maubeuge   (France)

^c UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Ceftazidime; Child; Continuous infusion; Neutropenic

Indexed keywords

AMIKACIN; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; VANCOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; B CELL LYMPHOMA; BONE MARROW APLASIA; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HUMAN; MORTALITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; TIME;

ADOLESCENT; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; CEFTAZIDIME; CHILD; CHILD, PRESCHOOL; FEVER; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; NEOPLASMS; NEUTROPENIA;

EID: 0036900924     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200212000-00006     Document Type: Article

References (25)

1. Gentry LO. Antimicrobial activity, pharmacokinetics, therapeutic indications and adverse reactions of ceftazidime. Pharmacotherapy, 1985;5:254-67.
2. Pizzo PA. Current issues in the antibiotic primary management of the febrile neutropenic cancer patient: A perspective from the National Cancer Institute. J Hosp Infect 1990;15(suppl A):41-8.
3. Ebert SC, Craig WA. Pharmacodynamic properties of antibiotics: Application to drug monitoring and dosage regimen design. Infect Control Hosp Epidemiol 1990;11:319-26.
4. Craig WA, Redington J, Ebert SC. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 1991;27(suppl C):29-40.
5. Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr 1986;108:835-40.
6. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: A review. Scand J Infect Dis Suppl 1990:74:63-70.
7. Craig WA, Ebert SC. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 1992;36:2577-83.
8. Vogelman BS, Craig WA. Postantibiotic effects. J Antimicrob Chemother 1985: 15(suppl A):37-46.
9. Gudmundsson S, Vogelman B, Craig WA. Decreased bactericidal activity during the period of the postantibiotic effect. J Antimicrob Chemother 1994;34:921-30.
10. Craig WA. Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. J Antimicrob Chemother 1993:31(suppl D):149-58.
11. MacGowan AP, Bowker KE. Continuous infusion of beta-lactam antibiotics. Clin Pharmacokinet 1998;35:391-402.
12. Jehl F, Birckel P, Monteil H. Hospital routine analysis of penicillins, third-generation cephalosporins and aztreonam by conventional and high-speed high-performance liquid chromatography. J Chromatogr 1987;413:109-19.
13. Bardin C, Vekhoff A, Leblanc F, et al. Pharmacocinetique de deux modes d'administration de la ceftazidime chez le patient neutropenique febrile: en perfusion continue et en injections discontinues. In: 18th Interdisciplinary Meeting on Anti-Infectious Therapy, December 1998, Paris.
14. Lemmen SW, Engels I, Daschner FD. Serum bactericidal activity of ceftazidime administered as continuous infusion of 3 g over 24 hours versus intermittent bolus infusion of 2 g against Pseudomonas aeruginosa in healthy volunteers. J Antimicrob Chemother 1997;39:841-2.
15. Mouton JW, Vinks AA, Punt NC. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 1997;41:733-8.
16. Mouton JW, Horrevorts AM, Mulder PG. et al. Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers. Antimicrob Agents Chemother 1990;34:2307-11.
17. Nicolau DP, Quintiliani R. Choosing between the new cephalosporin antibiotics: A pharmacodynamic approach. Pharmacoeconomics 1994;5(suppl):34-9.
18. Nicolau DP, Nightingale CH, Banevicius MA et al. Serum bactericidal activity of ceftazidime: Continuous infusion versus intermittent injections. Antimicrob Agents Chemother 1996;40:61-4.
19. Nicolau DP, McNabb J, Lacy MK, et al. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001;17:497-504.
20. Lipman J, Gomersall CD, Gin T, et al. Continuous infusion ceftazidime in intensive care: A randomized controlled trial. J Antimicrob Chemother 1999;43:309-11.
21. Daenen S, de Vries-Hospers H. Cure of Pseudomonas aeruginosa infection in neutropenic patients by continuous infusion of ceftazidime. Lancet 1988;1(8591):937.
22. David TJ, Devlin J. Continuous infusion of ceftazidime in cystic fibrosis. Lancet 1989;1(8652):1454-5.
23. Kuzemko J, Crawford C. Continuous infusion of ceftazidime in cystic fibrosis. Lancet 1989;2(8659):385.
24. LeNormand Y, Avetloiseau H, Kergueris M, et al. Ceftazidime and vancomycin constant-rate infusion in neutropenic children: Pharmacokinetic parameters and clinical implications. In: 33th ICAAC, October 1993, New Orleans.
25. Daenen S, Erjavec Z, Uges DR, et al. Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia. Eur J Clin Microbiol Infect Dis 1995;14:188-92.